My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

3.475 +0.465 (+15.45%)
Streaming Delayed Price Updated: 12:40 PM EDT, Sep 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR
Intellia led a rally for CRISPR stocks on Monday on early promise for its gene-editing drug. The news sent NTLA stock to a record high. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 62.0% to $143.91 during Monday's pre-market session. The company's market cap stands at $9.8 billion.... 
Via Benzinga
Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks
Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics. 
Via InvestorPlace
Why Editas Medicine Stock Is Jumping 13.9% This Week
The company received a go-ahead to enroll kids in a study of its lead gene-editing candidate. 
Via The Motley Fool
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
What's the Best Way to Invest in Genetics Stocks?
Here are some of our experts' favorite gene editing plays for the long run. 
Via The Motley Fool
Is Editas the Best Genetics Stock to Buy?
There are some big opportunities in the gene editing space. 
Via The Motley Fool
Earnings Roundup: General Motors, Editas Medicine, Activision Blizzard, Match Group
What we're learning during earnings season. 
Via The Motley Fool
Editas Medicine, Inc. (EDIT) Q1 2021 Earnings Call Transcript
EDIT earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
What Really Mattered With Editas Medicine's Q1 Update
It wasn't the biotech's financial performance. 
Via The Motley Fool
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2021
Upgrades For Genuine Parts Co (NYSE:GPC), Goldman Sachs upgraded the previous rating of Sell to Neutral. In the first quarter, Genuine Parts showed an EPS of $1.50,... 
Via Benzinga
Best Biotech Stocks & ETFs for mRNA, Gene Editing
2020 was the most challenging year in decades but it was great for scientific innovation, particularly in the biotech space. 
Via Talk Markets
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 11.8% to $1.61 during Friday's pre-market session. The market value of their outstanding shares is at $205.... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers INmune Bio (NASDAQ:INMB) stock rose 26.18% to $13.59 during Monday's regular session. As of 08:06 EST, this security is trading at a volume of 560.6K shares,... 
Via Benzinga
54 Biggest Movers From Friday
Gainers Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) shares surged 73.9% to close at $31.30 on Friday after the company priced its IPO at $18 per share. General Finance... 
Via Benzinga
Topics Initial Public Offering
CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today
A "sell" rating is one thing, but a 50% price target? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it. 
Via InvestorPlace
Nasdaq Stays Flat as Workhorse Drives Higher, Editas Sinks
Investors are trying to figure out which stocks have the best prospects. 
Via The Motley Fool
Topics Stocks
Why Editas Medicine Stock Is Getting Crushed Today
Investors are running for the hills following this analyst take on the biotech's prospects. 
Via The Motley Fool
38 Stocks Moving In Friday's Mid-Day Session
Gainers Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) shares jumped 78.1% to $32.06 after the company priced its IPO at $18 per share. General Finance Corporation (NASDAQ: GFN)... 
Via Benzinga
Topics Initial Public Offering
Benzinga's Top Ratings Upgrades, Downgrades For April 16, 2021
Upgrades According to Argus Research, the prior rating for United Airlines Holdings Inc (NASDAQ:UAL) was changed from Hold to Buy. In the fourth quarter, United Airlines... 
Via Benzinga
3 Biotech Stocks Ripe for Spring Portfolio Cleaning
All down 45% or more from their 52-week highs, should you consider cutting your losses? 
Via The Motley Fool
Biotech Stocks Hit A Snag — Why Experts Say The Heyday Isn't Over
Regulatory and drug-pricing worries have knocked biotech stocks off their pedestal. After hitting a high point in February, biotech stocks have fallen 20%. 
Via Investor's Business Daily
Spring Cleaning for Investors
Start this year's spring cleaning by asking yourself the right questions. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.